Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

[1] Pfreundschuh M(2006)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group Lancet Oncol 7 379-391

[2] Trümper L(2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 105-116

[3] Osterborg A(2017)Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma J Clin Oncol 35 3529-3537

[4] Pfreundschuh M(1993)A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987-994

[5] Schubert J(2010)Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era J Clin Oncol 28 2373-2380

[6] Ziepert M(2007)The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 1857-1861

[7] Vitolo U(2014)An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Blood 123 837-842

[8] Trněný M(2013)Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma N Engl J Med 369 1681-1690

[9] Belada D(2014)Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group J Clin Oncol 32 3048-3058

[10] Ziepert M(1999)Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group Eur J Cancer 35 1773-1782

[1] Pfreundschuh M(2006)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group Lancet Oncol 7 379-391

[2] Trümper L(2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 105-116

[3] Osterborg A(2017)Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma J Clin Oncol 35 3529-3537

[4] Pfreundschuh M(1993)A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987-994

[5] Schubert J(2010)Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era J Clin Oncol 28 2373-2380

[6] Ziepert M(2007)The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 1857-1861

[7] Vitolo U(2014)An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Blood 123 837-842

[8] Trněný M(2013)Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma N Engl J Med 369 1681-1690

[9] Belada D(2014)Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group J Clin Oncol 32 3048-3058

[10] Ziepert M(1999)Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group Eur J Cancer 35 1773-1782